Current strategies in the treatment of metastatic hormone-refractory prostate cancer.

Suppr

超能文献

作者信息

Ghosn Marwan, Kattan Joseph, Younes Fariha

机构信息

Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.

出版信息

Tunis Med. 2005 Dec;83 Suppl 12:74.

PMID:16430073

Abstract

摘要

相似文献

Current strategies in the treatment of metastatic hormone-refractory prostate cancer.

Tunis Med. 2005 Dec;83 Suppl 12:74.

Hormone-refractory prostate cancer: what have we learned?

BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x.

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.

Cancer. 2008 Apr 15;112(8):1660-71. doi: 10.1002/cncr.23318.

[Treatment of hormonal refractory metastatic prostate cancer].

Ugeskr Laeger. 2007 May 14;169(20):1905-7.

[Treatment of locally spread prostate cancer].

Duodecim. 2005;121(16):1779-82.

[Early versus late hormonal treatment in advanced prostate cancer].

Actas Urol Esp. 1999 Jul-Aug;23(7):557-64.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11.

Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy.

Clin Nucl Med. 2004 Feb;29(2):81-5. doi: 10.1097/01.rlu.0000109721.58471.44.

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?

Nat Clin Pract Urol. 2006 Jun;3(6):310-1. doi: 10.1038/ncpuro0504.

Prostate cancer chemotherapy: emerging from the shadows.

J Clin Oncol. 2005 May 20;23(15):3302-3. doi: 10.1200/JCO.2005.11.933. Epub 2005 Feb 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Current strategies in the treatment of metastatic hormone-refractory prostate cancer.

Tunis Med. 2005 Dec;83 Suppl 12:74.

Hormone-refractory prostate cancer: what have we learned?

BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x.

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.

Cancer. 2008 Apr 15;112(8):1660-71. doi: 10.1002/cncr.23318.

[Treatment of hormonal refractory metastatic prostate cancer].

Ugeskr Laeger. 2007 May 14;169(20):1905-7.

[Treatment of locally spread prostate cancer].

Duodecim. 2005;121(16):1779-82.

[Early versus late hormonal treatment in advanced prostate cancer].

Actas Urol Esp. 1999 Jul-Aug;23(7):557-64.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11.

Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy.

Clin Nucl Med. 2004 Feb;29(2):81-5. doi: 10.1097/01.rlu.0000109721.58471.44.

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?

Nat Clin Pract Urol. 2006 Jun;3(6):310-1. doi: 10.1038/ncpuro0504.

Prostate cancer chemotherapy: emerging from the shadows.

J Clin Oncol. 2005 May 20;23(15):3302-3. doi: 10.1200/JCO.2005.11.933. Epub 2005 Feb 28.